Loading clinical trials...
Loading clinical trials...
Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance
Conditions
Interventions
Selumetinib
Olaparib
Locations
1
United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
August 4, 2017
Primary Completion Date
August 30, 2026
Completion Date
August 30, 2026
Last Updated
April 15, 2026
NCT07067138
NCT06878248
NCT03093909
NCT04669873
NCT03165487
NCT02204098
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions